Cambium Bio (ASX:CMB) Dividend Yield % : 0.00% (As of Jun. 20, 2024)

View and export this data going back to 2013. Start your Free Trial

What is Cambium Bio Dividend Yield %?

As of today (2024-06-20), the Trailing Annual Dividend Yield of Cambium Bio is 0.00%.

The historical rank and industry rank for Cambium Bio's Dividend Yield % or its related term are showing as below:

ASX:CMB's Dividend Yield % is not ranked ^*
in the Biotechnology industry.
Industry Median: 1.6
* Ranked among companies with meaningful Dividend Yield % only.

Cambium Bio's Dividend Payout Ratio for the six months ended in Dec. 2023 was 0.00.

As of today (2024-06-20), the Forward Dividend Yield % of Cambium Bio is 0.00%.

Cambium Bio's Dividends per Share for the six months ended in Dec. 2023 was A$0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Cambium Bio Dividend Yield % Historical Data

The historical data trend for Cambium Bio's Dividend Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cambium Bio Dividend Yield % Chart

Cambium Bio Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Dividend Yield %

Get a 7-Day Free Trial

Cambium Bio Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Dividend Yield %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Cambium Bio's Dividend Yield %

For the Biotechnology subindustry, Cambium Bio's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cambium Bio's Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cambium Bio's Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Cambium Bio's Dividend Yield % falls into.

Cambium Bio Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

Cambium Bio (ASX:CMB) Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

Cambium Bio Dividend Yield % Related Terms

Thank you for viewing the detailed overview of Cambium Bio's Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Cambium Bio (ASX:CMB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cambium Bio Ltd (ASX:CMB) » Definitions » Dividend Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

16 Goodhope Street, Paddington, Sydney, NSW, AUS, 2021

Website

https://www.regeneus.com.au

Regeneus Ltd is a clinical-stage regenerative medicine company in Australia. It mainly develops a portfolio of cell-based therapies to address unmet medical needs in the human and animal health markets with a focus on osteoarthritis and other musculoskeletal disorders, oncology and dermatology diseases. The company uses stem cell and immuno-oncology technologies to develop cell-based therapies. Its product pipeline consists of two platform technologies, Progenza and Sygenus, across three target therapeutic areas namely osteoarthritis, neuropathic pain, and skin wound healing. The company has one operating segment being the development of innovative cell-based therapies to address significant unmet medical needs in human and veterinary health.

Cambium Bio (ASX:CMB) Headlines

No Headlines